Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
Coppini R, Mazzoni L, Ferrantini C, Gentile F, Pioner JM, Laurino A, Santini L, Bargelli V, Rotellini M, Bartolucci G, Crocini C, Sacconi L, Tesi C, Belardinelli L, Tardiff J, Mugelli A, Olivotto I, Cerbai E, Poggesi C. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy. Circ Heart Fail. 2017 03; 10(3).
-
Animals
-
Blotting, Western
-
Calcium-Calmodulin-Dependent Protein Kinases
-
Cardiomyopathy, Hypertrophic
-
Disease Models, Animal
-
Echocardiography, Doppler
-
Excitation Contraction Coupling
-
Genetic Predisposition to Disease
-
Heart Rate
-
Hypertrophy, Left Ventricular
-
Magnetic Resonance Imaging
-
Male
-
Membrane Potentials
-
Mice, Inbred C57BL
-
Mice, Transgenic
-
Microscopy, Confocal
-
Mutation
-
Myocardial Contraction
-
Myocytes, Cardiac
-
Phenotype
-
Ranolazine
-
Sodium
-
Sodium Channel Blockers
-
Time Factors
-
Troponin T
-
Ventricular Dysfunction, Left
-
Ventricular Function, Left